Gerresheimer CEO dubs weight-loss drugs a meaningful positive catalyst

Dietmar Siemssen – the chief executive of Gerresheimer AG (ETR: GXI) expects strong demand for weight-loss drugs to be a meaningful tailwind for his company.

Weight-loss drugs to boost $GXI revenue growth

Siemssen expects supply of vials, syringes, cartridges, and autoinjectors to makers of GLP-1 drugs to account for about 4.0% of revenue growth per year for Gerresheimer.

In February, the manufacturer based out of Dusseldorf, Germany had called for a 10% yearly growth on average. So, close to half of it will likely be attributed to Gerresheimer’s supply deals with the likes of Eli Lilly and Novo Nordisk.

CEO Dietmar Siemssen made that forecast in a recent interview with Reuters.

The news arrives more than a month after $GXI reported a 3.0% year-on-year growth in revenue for its fiscal fourth quarter.

Estimates for the weight-loss drugs market

Siemssen also told Reuters last week that GLP-1 relates sales of his company will surpass $380 million over the next three years.

We are just at the beginning of the ramp up towards the total market for (these drugs), and the biggest growth you will see from 2025 to 2027.

Wegovy of Novo Nordisk and Zepbound of Eli Lilly & Co together are broadly expected to exceed $12 billion in sales this year and $23 billion in 2025.

All in all, analysts are convinced that anti-obesity drugs will be a $100 billion market at least by 2030. Note that Gerresheimer AG currently pays a dividend yield of about 1.20%.